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ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) has a high capacity for invasion. 
To identify microRNAs (miRNAs) that regulate HNSCC invasion, we compared miRNA 
expression profiles between a parent HNSCC cell line and a highly invasive clone. The 
miR-200 family and miR-203 were downregulated in the clone. Here we focused on 
the role of miR-203 in invasion and epithelial-mesenchymal transition (EMT) induction 
in HNSCC. miR-203 was downregulated during EMT induction. Moreover, ectopic 
overexpression of miR-203 suppressed the invasion and induced mesenchymal-
epithelial transition (MET) in HNSCC cells. Interestingly, we identified NUAK family 
SNF1-like kinase 1 (NUAK1) as a novel target gene of miR-203 by cyclopedic analysis 
using anti-Ago2 antibody. Increased expression of NUAK1 was observed during EMT 
induction, and ectopic expression of miR-203 delayed EMT induction by suppressing 
NUAK1 expression. Moreover, NUAK1 overexpression promoted the invasion of HNSCC 
cells. Importantly, NUAK1 expression was well correlated with poor differentiation, 
invasiveness, and lymph node metastasis in HNSCC cases. Overall, miR-203 has a 
tumor-suppressing role in invasion and EMT induction by targeting NUAK1 in HNSCC, 
suggesting miR-203 as a potential new diagnostic and therapeutic target for the 
treatment of HNSCC.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is one of the most common types of human cancer, with an 
annual incidence of more than 500,000 cases worldwide 
[1]. HNSCC is associated with severe disease- and 
treatment-related morbidity, and has a 5-year survival 
rate of approximately 50%; this rate has not improved in 
more than two decades [2]. Cancerous metastasis is the 
most important prognostic factor of HNSCC as in other 
carcinomas [3]. Like most epithelial cancers, HNSCC 
results from the accumulation of genetic and epigenetic 
alterations in a multistep process. In early metastasis, 
cancer cells experience reduced cell-to-cell adhesion 
and increased mobility through epithelial-mesenchymal 
transition (EMT), by which the phenotype of the cells 
changes from epithelial to mesenchymal [4]. During 
EMT, cancer cells become detached from each other. 
This results from decreased E-cadherin expression due 
to hypermethylation of the gene’s promoter region, or 
transcriptional repression caused by zinc finger E-box-
binding homeobox 1 and 2 (ZEB1, ZEB2), Snail family 
zinc finger 1 and 2 (SNAI1, SNAI2), and Twist family 
bHLH transcription factor 1 (TWIST) [5,6].
microRNAs (miRNAs) are a class of highly 
conserved, 18-25-nucleotide, small non-coding RNAs 
that decrease the expression of certain genes through 
translational repression or mRNA degradation. They 
play important roles not only in various biological 
processes including cell proliferation, stress resistance, 
and metabolism, but also in pathogenesis. Recently, many 
reports have shown that several miRNAs have oncogenic 
or tumor-suppressive activities [7,8]. Of these, members 
of the miR-200 family (miR-200a, -200b, -200c, -141, and 
-429) have shown the greatest activity during EMT [9]. 
The miR-200 family directly suppresses ZEB1/ZEB2 and 
maintains E-cadherin expression [10–12].
In a previous study, we established MSCC-1 
cells from a cervical lymph node metastasis of gingival 
squamous cell carcinoma (SCC) [13]. Subsequently, a 
highly invasive MSCC-inv1 clone was isolated from 
MSCC-1 cells using an in vitro invasion assay [14]. 
Moreover, we identified several molecules including 
periostin by comparing the transcriptional profiles of 
MSCC-1 and MSCC-inv1 [15]. Interestingly, MSCC-inv1 
has EMT features such as spindle shape and decreased 
E-cadherin expression compared with parental MSCC-
1. Here, we compared the miRNA expression profiles 
between these two cell lines to identify the microRNAs 
that differ in their expression. We identified the miR-200 
family and miR-203 as having the most downregulated 
expression in the highly invasive clone. Because it is well 
known that the miR-200 family plays an important role 
in invasion and EMT in cancer, we focused on the role of 
miR-203 in EMT induction and invasion in HNSCC.
RESULTS
miR-203 and the miR-200 family are identified 
as downregulated genes in a highly invasive 
HNSCC cell line
We compared the miRNA expression profiles 
between a parent cell line (MSCC-1) and a highly invasive 
clone (MSCC-inv1) by microarray analysis to identify 
genes that differed in their expression (Figure 1A). 
Several miRNAs were selectively downregulated in the 
clone (Figure 1A and Supplementary data 1). Among these 
genes, the miR-200 family (miR-200a, -200b, -200c, and 
-141) and miR-203 were included. We then confirmed the 
expression of these miRNAs in MSCC-1 and MSCC-inv1 
cells (Figure 1B). We examined the expression of the miR-
200 family (miR-200a, -200b, -200c and -141) and miR-
203 in cells with the epithelial phenotype (HaCaT, HSC2, 
and MSCC-1) and EMT-induced cells (MSCC-inv1, 
HOC313, KOSCC25B, KOSCC33A, and SpSCC) by 
real-time PCR. EMT-induced cells, but not cells with the 
epithelial phenotype, showed no expression of E-cadherin 
and high expression of ZEB1 and ZEB2 (Figure 2A). In 
EMT-induced cells, all miRNAs tended to show lower 
expression levels in comparison with cells with the 
epithelial phenotype (Figure 2B). In particular, miR-200c, 
-203, and -141 were downregulated in all EMT-induced 
cells. Constructing a heat map from the results of real-time 
PCR, we identified similar expression tendencies between 
miR-141 and miR-200c, and between miR-200a and miR-
200b (Figure 2C). It is worth noting that two pairs of 
miRNAs form clusters because their chromosomal sites 
are close and their seed sequences are similar. However, 
miR-203 showed a unique expression profile among these 
miRNAs.
We next examined expression of the miR-200 
family (miR-200a, -200b, -200c, and -141) and miR-203 
in an EMT-induction model using NMuMG cells. It has 
been reported that the miR-200 family is downregulated 
during EMT-induction [16]. After TGF-β treatment, 
NMuMG cells became spindle-shaped with decreased 
expression of E-cadherin and increased expression of 
E-cadherin repressors including SNAI1, SNAI2, ZEB1, 
and ZEB2 (Figure 2D and 2E). During EMT induction 
by TGF-β treatment, miR-203, miR-200a, -200b and 
-200c experienced time-dependent downregulation, but 
we did not detect miR-141 downregulation (Figure 2F 
and Supplemental Figure 1A). We transfected miR-
200a, -200b, -200c, -141, and -203 into MSCC-inv1 
cells. Transfection with all mature miRNAs induced 
mesenchymal-epithelial transition (MET) shown by 
increased expression of E-cadherin (Supplemental 
Figure 1B). Moreover, we removed each miRNA from 
transfection. Interestingly, all conditions of mature 
miRNAs transfection using four of five miRNAs induced 
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MET, indicating that miR-200a, -200b, -200c, -141, 
and -203 play an important role in EMT induction in 
cooperation with each other (Supplemental Figure 1B). 
Because it is well known that the miR-200 family is 
involved in EMT [10–12], we focused on miR-203 as 
a candidate for an invasion- and/or EMT-suppressive 
miRNA in HNSCC cells.
miR-203 suppresses the invasion of HNSCC cells 
in vitro
We examined miR-203 expression in HNSCC cell 
lines. As shown in Figure 3A, miR-203 expression was 
significantly downregulated in EMT-induced HNSCC 
cells. To determine the role of miR-203 in HNSCC 
invasion, we transfected mature miR-203 into MSCC-inv1 
cells. Although previous reports have shown that miR-
203 suppresses cell proliferation in lung and esophageal 
cancer [17,18], miR-203 did not influence proliferation in 
MSCC-inv1 cells (Supplemental Figure 2A). Interestingly, 
miR-203 suppressed the invasion of MSCC-inv1 cells 
(Supplemental Figure 2B). To ensure that mature miRNA 
does not function at a supraphysiological level, we 
repeated these experiments using a miRNA vector that 
mimics miRNA biological processing. A pre-miR-203 
lentiviral construct that stably expressed the miR-203 
precursor in its native context was used to study the 
effect of miR-203 on MSCC-inv1 cell invasion (Figure 
3B). Interestingly, pre-miR-203-infected MSCC-inv1 
cells displayed a polygonal shape with upregulation of 
E-cadherin expression (Figure 3C and 3D). Pre-miR-203-
infected MSCC-inv1 cells had lower invasion capability 
(Figure 3E). Moreover, to decrease endogenous miR-
203 levels, HSC2 cells with epithelial phenotype were 
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Figure 1: Identification of miR-200 family and miR-203 as candidate genes for suppression of invasion and/or EMT 
in HNSCC. A. Schematic representation of miRNA expression profiles between parent cells (MSCC-1) and a highly invasive clones 
(MSCC-inv1). MSCC-inv1 cells were isolated from MSCC-1 cells by in vitro invasion assay. MSCC-inv1 cells are spindle shaped, while 
MSCC-1 cells are cobblestone-like shaped. The miRNA expression profile was examined by microarray. The table shows the top five 
downregulated miRNAs in MSCC-inv1 cells in comparison with MSCC-1 cells. B. Expression of the top five downregulated miRNAs 
in MSCC-inv1 cells was confirmed by real-time PCR. The graph shows the expression of these miRNAs (miRNA/U6) in MSCC-1 and 
MSCC-inv1 cells. All results are presented as means ± SD. *P < 0.05.
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Figure 2: miR-200 family and miR-203 expression are correlated with EMT-induced phenotype in HNSCC. A. Expression 
of E-cadherin, ZEB1, and ZEB2 was examined by RT-PCR in cells with epithelial phenotype (HaCaT, HSC2, and MSCC-1) and in EMT-
induced cells (MSCC-inv1, HOC313, KOSCC25B, KOSCC33A, and SpSCC). GAPDH was used as a control. B. Expression of miR-200a, 
-200b, -200c, -141, and -203 was examined by real-time PCR in cells with epithelial phenotype (HaCaT, HSC2, and MSCC-1) and in 
EMT-induced cells (MSCC-inv1, HOC313, KOSCC25B, KOSCC33A, and SpSCC). Expression of these miRNAs in HNSCC cells was 
normalized by that in normal keratinocytes (HaCaT). The graph shows the relative quantity of miRNAs (miR-200a, -200b, -200c, -203, 
and -141). C. The heat map of the miRNA expression of the experiment described above is shown. D. NMuMG cells were treated with 
10 ng/mL of TGF-β. The figure shows the cell shape at 0 (no treatment) and 48 h after TGF-β treatment. E. Expression of E-cadherin, 
SNAI1, SNAI2, ZEB1, and ZEB2 mRNA was examined by real-time PCR at 0, 12, 24, and 48 h (n = 3) after treatment with 10 ng/mL of 
TGF-β in NMuMG cells. The graph shows the expression of these mRNAs (mRNA/GAPDH). All results are presented as means ± SD. 
**P < 0.01, *P < 0.05. F. Expression of miR-203 was examined by real-time PCR at 0, 12, 24, and 48 h (n = 3) after treatment with 10 ng/
mL of TGF-β in NMuMG cells. The graph shows the expression levels of miR-203 normalized by U6. The results are presented as means 
± SD and *P < 0.05.
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Figure 3: miR-203 suppresses cancerous invasion of HNSCC cells. A. Expression of miR-203 was examined by real-time PCR in 
cells with epithelial phenotype (HaCaT, HSC2, and MSCC-1) and EMT-induced cells (MSCC-inv1, HOC313, KOSCC25B, KOSCC33A, 
and SpSCC). The graph shows miR-203/U6. The results are presented as means ± SD. *P < 0.05. B. Expression vector of pre-miR-203 
or scramble negative control vector was transfected into MSCC-inv1 cells. miR-203/U6 was examined by real-time PCR and data were 
normalized to negative control-transfected samples. The results are presented as means ± SD. *P < 0.05. C. The figure shows the cell shape 
of control- and pre-miR-203-infected MSCC-inv1 cells. D. Expression of E-cadherin and NUAK1 mRNA was examined by real-time PCR 
in control- and pre-miR-203-infected MSCC-inv1 cells. The graph shows the expression of these mRNAs (mRNA/GAPDH). All results 
are presented as means ± SD. *P < 0.05. E. The graph shows invasion capability of negative control- or pre-miR-203-infected MSCC-inv1 
cells. The invasiveness of the cells was determined by in vitro invasion assay for 9 h. **P < 0.01. F. HSC2 cells with miR-203 expression 
were transfected with miR-203 inhibitor (5, 25, 50, and 75 nM). The invasiveness of the cells was determined by in vitro invasion assay 
for 22 h. *P < 0.05.
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transfected with a specific miR-203 inhibitor. As shown 
in Figure 3F, the miR-203 inhibitor enhanced the invasion 
capability of the HSC2 cells. Collectively, these results 
suggest that miR-203 plays an important role in the 
invasion of HNSCC cells.
NUAK1 is a target gene of miR-203
Protein-coding mRNA transcripts that serve as 
target genes for miRNAs are bound indirectly to the 
Argonaute (Ago)-containing RNA-induced silencing 
complex (RISC). Therefore, to determine the target 
genes of miR-203, we used an antibody against wild-
type human Ago2 to immunoprecipitate the RISC from 
the total cell lysate of MSCC-inv1 cells with or without 
ectopic miR-203 overexpression (Figure 4A). Ago2 is 
a member of the Ago family found in RISC complexes 
[19]. Because the available evidence suggests that binding 
among Ago family members is not sequence-specific 
[20,21], Ago2 binding is expected to serve as a proxy for 
binding with all Ago proteins. We prepared RNAs from 
immunoprecipitated extracts of control- or miR-203-
transfected MSCC-inv1 cells with anti-Ago2 antibody 
for microarray analysis. In MSCC-inv1 cells with ectopic 
miR-203 expression, 805 genes were enriched at least 
2-fold over the control cells (Figure 4B and Supplementary 
data 2). In addition, we searched the website, Target Scan 
Human 6.2 (http://www.targetscan.org/) for direct targets 
of miR-203 [22]. By using Target Scan algorithm analysis, 
1059 genes are predicted as target genes of miR-203. 
Sixty-three genes overlapped between our analysis and the 
Target Scan algorithm analysis (Figure 4B). Among those 
63 genes, 13 (GALNT7, KIF2A, NLK, NUAK1, VEGFA, 
LIN7C, LMO4, SP1, STEAP1, OCLN, PKD2, RAB3B, 
and SNAI2) are previously reported as a gene involved 
in cancer, invasion, and EMT, and FUBP3 showed 
considerable upregulation with miR-203 transfection in 
Ago2-IP analysis (Supplemental Table 1). Therefore, we 
focused on those 14 genes as candidates for miR-203 
target genes (Figure 4B). SNAI1, SNAI2, ZEB2, and 
VEGFA have been reported as miR-203 targets related 
to cancer invasion [23–28]. Interestingly, SNAI2 and 
VEGFA were included in the 14 candidate target genes of 
miR-203. Among the 14 genes, 7 (NUAK1, VEGFA, SP1, 
OCLN, PKD2, RAB3B, and SNAI2) were downregulated 
by mature miR-203 transfection (Figure 4B, 4C, and 
Supplemental Figure 3A). Of those 7 genes, NUAK1, 
SNAI2, VEGFA, and PKD2 were upregulated by miR-203 
inhibitor transfection (Figure 4B, 4D, and Supplemental 
Figure 3B). NUAK1 and SNAI2 were significantly 
upregulated (Figure 4D). NUAK1 expression in the 
MSCC-inv1 cells was slightly higher than in the MSCC-
1 cells (Supplemental Figure 3C). SNAI2 expression in 
the MSCC-inv1 cells was similar to that in the MSCC-1 
cells (Supplemental Figure 3C). SNAI2 has been identified 
as a target gene of miR-203 in breast and prostate cancer 
[26–28], and we confirmed that mature miR-203 decreased 
the relative luciferase activity of the 3ʹ-UTR reporter 
vectors by approximately 50-70% (Supplemental Figure 
4A). Pre-miR-203-infected MSCC-inv1 cells showed 
slightly lower expression of SNAI2 (Supplemental Figure 
4B). Moreover, mature miR-203 transfection decreased 
the expression of SNAI2 in EMT-induced HNSCC cells 
(HOC313 and SpSCC) (Supplemental Figure 4C), and 
miR-203 inhibitor transfection increased the expression 
of SNAI2 in HSC2 cells of epithelial phenotype 
(Supplemental Figure 4D). Here, we focused on NUAK1 
as a candidate novel target gene of miR-203.
To investigate whether miR-203 is able to directly 
target NUAK1 by interacting with its 3ʹ-UTR in vitro, the 
3ʹ-UTR of NUAK1 was cloned and inserted downstream 
of a luciferase reporter gene. Subsequently, the mature 
miR-203 or control miRNA were cotransfected with 
3ʹ-UTR reporter vectors into 293T cells. The mature 
miR-203 decreased the relative luciferase activity of the 
3ʹ-UTR reporter vector by approximately 50% (Figure 
5A). Indeed, mature miR-203 transfection decreased the 
expression of NUAK1 in EMT-induced HNSCC cells 
(KOSCC25B, SpSCC, and HOC313) (Figure 5B), and 
NUAK1 was downregulated in pre-miR-203-infected 
MSCC-inv1 cells (Figure 3D). Moreover, miR-203 
inhibitor transfection increased the expression of NUAK1 
in HSC2 cells of epithelial phenotype (Figure 5C). In the 
HNSCC cell lines, miR-203 expression was not always 
inversely correlated with NUAK1 expression, but inverse 
correlation between miR-203 and NUAK1 was observed 
in MSCC-1, HOC313, KOSCC25B, and SpSCC (data not 
shown). Thus, we demonstrated that NUAK1 is a novel 
target gene for miR-203 in HNSCC cells.
NUAK1 is involved in invasion and EMT 
induction in HNSCC
To determine the involvement of NUAK1 in 
invasion and EMT induction, we examined NUAK1 
expression in an EMT induction model using A549 cells. 
As far as we know, there is no EMT induction model using 
HNSCC cells. Therefore, we used NMuMG cells and 
A549 cells as an EMT-inducing model in this study. After 
48 h of TGF-β treatment, the cells showed EMT features 
such as spindle shape, downregulation of E-cadherin, and 
upregulation of N-cadherin, SNAI1, SNAI2, ZEB1, and 
vimentin (Figure 6A). NUAK1 expression increased in a 
time-dependent way after TGF-β treatment (Figure 6A). 
We also confirmed that increased NUAK1 expression 
was observed in another EMT induction model using 
NMuMG cells (Supplemental Figure 5). Moreover, we 
examined NUAK1 expression in stable pre-miR-203-
infected A549 cells after TGF-β treatment. In stable 
pre-miR-203-infected A549 cells, miR-203 delayed the 
EMT induction shown by downregulation of E-cadherin 
and upregulation of N-cadherin after TGF-β treatment 
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Figure 4: NUAK1 was identified as a target gene of miR-203. A. Schematic representation of the process of finding the target 
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expression, 805 genes were enriched at least 2-fold over controls. By using Target Scan algorithm analysis (http://www.targetscan.org/), 1059 
genes were predicted as target genes of miR-203. Sixty-three genes overlapped in the two analyses. Among those 63 genes, 14 were picked 
up by previous reports on the involvement of cancer, invasion, and EMT (Supplemental Table 1) and the result of Ago2-IP microarray. We 
then screened these genes by mature miR-203 transfection and miR-203 inhibitor transfection. Finally, we identified NUAK1 and SNAI2 
as target genes of miR-203. C. The graph shows the expression of candidate genes of miR-203 (OCLN, PKD2, SP1, RAB3B, VEGFA, 
NUAK1, and SNAI2) in control- or mature miR-203-transfected MSCC-inv1 cells. The graph shows the expression of these mRNAs 
(mRNA/GAPDH). The results are presented as means ± SD. **P < 0.01. D. The graph shows the expression of NUAK1, SNAI2, VEGFA, 
and PKD2 in control- or miR-203 inhibitor-transfected HSC2 cells. The graph shows the expression of these mRNAs (mRNA/GAPDH). 
The results are presented as means ± SD. **P < 0.01, *P < 0.05.
Oncotarget8230www.impactjournals.com/oncotarget
(Figure 6B). Interestingly, increased expression of 
NUAK1 and SNAI2 was inhibited in stable pre-miR-
203-infected A549 cells after TGF-β treatment (Figure 
6B), suggesting that miR-203 downregulation may be 
important for EMT induction via NUAK1 upregulation. 
However, ectopic overexpression of NUAK1 itself did not 
induce EMT (data not shown).
To determine the role of NUAK1 in the invasion of 
HNSCC cells, we transfected NUAK1 into HSC2 cells 
with low NUAK1 expression levels. In the HSC2 cells, 
NUAK1 overexpression promoted invasion (Figure 6C 
and 6D). In contrast, we transfected NUAK1 siRNA into 
SpSCC cells with NUAK1 expression, and found that 
NUAK1 siRNA suppressed the invasion of SpSCC cells 
(Figure 6E and 6F). Overexpression or knockdown of 
NUAK1 did not change cell morphology (data not shown). 
These findings indicate that NUAK1 is involved in the 
invasion of HNSCC cells.
Downregulation of miR-203 is caused by 
hypermethylation in HNSCC
Because miR-203 is downregulated by promoter 
hypermethylation in some human cancers [29–32], we 
tested whether this was also the case in HNSCC cells. The 
genomic DNA was isolated, treated with bisulfite, and 
then subjected to methylation-specific PCR (MS-PCR). 
Interestingly, a methylated band was observed in all 
HNSCC cells with an EMT-induced phenotype, but not in 
cells with an epithelial phenotype (Figure 7A). Moreover, 
demethylation by 5-aza-2ʹ-deoxycytidine (5-aza-dC) 
treatment increased miR-203 expression in MSCC-inv1 
cells compared with MSCC-1 cells (Figure 7B). In other 
HNSCC cells with an EMT-induced phenotype, 5-aza-dC 
treatment also increased miR-203 expression (Figure 7C). 
In 5-aza-dC-treated HNSCC cells, NUAK1 expression 
was not always downregulated (Supplemental Figure 
6). SNAI2 expression was downregulated by 5-aza-
dC treatment (Supplemental Figure 6). Collectively, 
these findings show that the expression of miR-203 was 
downregulated in HNSCC cells with an EMT-induced 
phenotype mainly by promoter hypermethylation.
NUAK1 expression is well correlated with the 
invasion pattern in HNSCC
We examined NUAK1 expression and its correlation 
with miR-203 and malignant behaviors including invasion 
pattern and lymph node metastasis in HNSCC cases. To 
determine the correlation between NUAK1 and miR-203, 
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we examined the expression of NUAK1 mRNA and miR-
203 in 33 HNSCC cases. In Supplemental Figure 7A, the 
graph shows the expression ratio of NUAK1/GAPDH 
and miR-203/U6 in each HNSCC case. In 16 of the 33 
(48%) cases, an inverse correlation between NUAK1 
and miR-203 was observed. In 13 of the 16 (81%) cases 
with inverse correlation, high NUAK1 expression and 
low expression of miR-203 were observed. Moreover, 
we examined NUAK1 expression and its correlation with 
malignant behaviors including histological differentiation, 
invasion pattern, and lymph node metastasis in 54 
HNSCC cases by immunohistochemistry. For evaluating 
the invasive pattern, we used the Yamamoto-Kohama 
(YK) classification. NUAK1 expression was observed in 
28 of the 54 (52%) HNSCC cases (Figure 8A and Table 
1). Interestingly, NUAK1 expression was well correlated 
with histological differentiation, invasion pattern, and 
lymph node metastasis (Table 1). In brief, NUAK1 
expression was well correlated with poor differentiation, 
aggressive invasion patterns (YK-4C and -4D), and lymph 
node metastasis (Figure 8B, Table 1, and Supplemental 
Figure 7B).
DISCUSSION
In this study, we identified miR-203 and the 
miR-200 family (miR-200a, -200b, -200c, and -141) as 
downregulated miRNAs by comparing miRNA expression 
profiles between a parent cell line and its clone with 
highly invasive capability and EMT features. Members 
of the miR-200 family are well known to be the most 
altered miRNAs during EMT [9]. In addition, miR-203 
downregulation has been described in various cancers 
including esophagus, cervix, prostate, breast, and liver 
cancer, and miR-203 inhibits cancerous invasion by 
targeting SNAI1, SNAI2, ZEB2, and VEGFA [23–28,32–
35]. The miRNAs identified in this study were commonly 
downregulated in HNSCC cell lines with EMT features 
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(Figure 2B). It is known that these miRNAs and their 
target genes including ZEB1/ZEB2 and SNAI1/SNAI2 are 
important factors for determining the phenotype of cells 
(epithelial or mesenchymal) [11,12,23-26,36]. Therefore, 
these observation and our findings lead us to hypothesize 
that the miR-200 family and miR-203 cooperatively 
maintain the epithelial state through a feedback loop via 
suppression of SNAI1/SNAI2 and ZEB1/ZEB2. Actually, 
ectopic expression of miR-203 and the miR-200 family 
caused restoration of E-cadherin (Supplemental Figure 
1B), and long-term induction of pre-miR-203 caused 
MET in MSCC-inv1 cells (Figure 3C and 3D). Moreover, 
transient induction of miR-203 upregulated expression 
levels of the miR-200 family (miR-200b, -200c, and -141) 
(data not shown). These data suggest the existence of a 
network comprising the miR-200 family and miR-203. In 
transient induction of EMT, downregulation of miR-203 
may be caused by downregulation of the miR-200 family 
and/or upregulation of SNAI1/SNAI2 and ZEB1/ZEB2 
(Figure 8C). To prove this, further analyses are necessary.
Because the miR-200 family has been well studied 
in the field of cancer, we focused here on the role of miR-
203 in EMT induction and invasion in HNSCC. Indeed, 
we demonstrated that miR-203 was downregulated 
during EMT induction by TGF-β, and that miR-203 
suppressed invasion of HNSCC cells. To identify the 
target genes of miR-203 involved in cancerous invasion, 
we performed microarray analysis using the total RNA 
prepared from extracts of the miR-203-transfected cells 
immunoprecipitated with anti-Ago2 antibody. This method 
can cyclopedically search a target gene in RISC. In fact, 
SNAI2 and VEGFA, which have been identified as targets 
of miR-203 [25–28], were included in the extracts of the 
miR-203-transfected cells immunoprecipitated with anti-
Ago2 antibody. Therefore, we thought that this method 
would be useful for searching the target genes. Here we 
identified NUAK1, which is involved in EMT induction 
and aggressive cancerous invasiveness of HNSCC cells, 
as a novel target gene. However, during the preparation 
of this manuscript, it has been reported that NUAK1 is 
a target gene of miR-203 for suppressing prometastatic 
activity via cell metabolism [37]. The researchers also 
identified LASP1 and SPARC as target genes of miR-
203 for the involvement of cytoskeletal dynamics and 
extracellular matrix remodeling [37]. Previous reports have 
suggested that miR-203 promotes epithelial differentiation 
by suppressing ΔNp63 and stemness related factor Bmi1 
[38,39]. It is widely accepted that cancer cells undergoing 
EMT become more “stem-like” [40]. In this study, during 
the miR-203 target search, we selected molecules related 
to cancerous invasion or EMT, but many transcription 
factors or chromatin remodeling-related genes are detected 
by Ago2-IP microarray (Supplemental Table 1). There 
may be other target genes of miR-203 that are involved 
in EMT and invasion in HNSCC. These findings suggest 
that miR-203 is a tumor suppressor miRNA that works by 
suppressing cell metabolism, stemness, EMT induction, 
and cancerous invasion. Importantly, hypermethylation 
of the CpG islands existing upstream on the miR-203 
chromosome is frequently found in various cancers 
including HNSCC (Figure 7) [30,32].
NUAK1 is a member of AMP-activated protein 
kinase (AMPK) catalytic subunit family [41]. AMPKs 
are highly conserved molecules that work as metabolic 
sensors, and their activity has been linked to the regulation 
of metabolism and to the maintenance of polarity under 
stress conditions [41]. NUAK1 is associated with 
cancerous invasion in breast and lung cancers, colorectal 
carcinoma, and multiple myeloma [42–45]. Here we 
demonstrated that NUAK1 is involved in the invasion 
and EMT induction of HNSCC. However, NUAK1 
overexpression and knockdown did not change the cell 
morphology or the expression of EMT-related molecules 
including E-cadherin, N-cadherin, vimentin, SNAI1, 
and SNAI2 (data not shown). This finding indicates that 
NUAK1 itself cannot induce EMT. As with SNAI1 and 
SNAI2, NUAK1 may be upregulated during EMT, and 
subsequently involved in the invasion of HNSCC cells 
Table 1: Summary of NUAK1 expression in HNSCC cases
Total
NUAK1 expression
P value
− +
Differentiation
Well
Moderate
Poor
24
24
6
17(71%)
9(38%)
0(0%)
7(29%)
15(63%)
6(100%)
0.00002
Pattern of invasion
2
3
4C
4D
5
24
20
5
5(100%)
19(79%)
2(10%)
0(0%)
0(0%)
5(21%)
18(90%)
5(100%)
0.00001
Lymph node metastasis −+
24
30
18(75%)
8(27%)
6(25%)
22(73%) 0.0003
Total 54 26(48%) 28(52%)
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(Figure 8C). Previous studies have shown that NUAK1 
activates MT1-MMP, which results in promoting the 
metastasis of breast and pancreatic cancer via activation of 
MMP-2 and MMP-9 [42,46], so miR-203-driven invasion 
of HNSCC cells may be regulated by a pathway that is 
distinct from EMT induction. Moreover, NUAK1 inhibits 
apoptosis and promotes proliferation and Myc expression 
in colon, liver, and lung cancer [47]. In this study, NUAK1 
siRNA did not influence the proliferation of HNSCC 
cells (data not shown). Importantly, NUAK1 expression 
was well correlated with histological differentiation, 
invasion pattern, and lymph node metastasis. Therefore, 
we believe that NUAK1 could be used as a novel marker 
for the prediction of malignant behavior in HNSCC. We 
expect that miR-203 may become a therapeutic drug for 
the inhibition of NUAK1 expression in the treatment for 
HNSCC.
MATERIALS AND METHODS
Plasmid construction
Human NUAK1 cDNA was isolated from the cDNA 
of the SpSCC cells by RT-PCR using sense and antisense 
primers. NUAK1 cDNA was then subcloned by insertion 
into the EcoRI restriction site of the pBICEP-CMV2 
expression vector (Sigma-Aldrich). The NUAK1-pBICEP-
CMV2 plasmid or the vector alone was introduced into 
target cells using an X-tremeGENE HP DNA Transfection 
Reagent (Roche Applied Science).
Cell culture and proliferation assay
MSCC-1 and MSCC-inv1 cells were previously 
established in our laboratory [13,14]. SpSCC cells 
were established from spindle cell carcinoma arising 
in the gingiva [48]. HeLa, 293T, HSC2, A549, and 
NMuMG cell lines were obtained from the American 
Type Culture Collection and Riken Bioresource Center 
Cell Bank (Japan). The HOC313 cell line was provided 
by Dr. Kamata (Hiroshima University, Japan). The 
KOSCC25B and KOSCC33A cell lines were provided by 
Dr. Sam-Pyo Hong (Seoul National University, Korea). 
The HaCaT cell line was provided by Dr. P. Boukamp 
(German Cancer Research Center, Germany). MSCC-1 
and MSCC-inv1 cells were maintained in Keratinocyte-
SFM (Invitrogen). HSC2, KOSCC25B, and KOSCC33A 
cells were maintained in RPMI-1640 medium (Nissui 
Pharmaceutical Co. Ltd.) supplemented with 10% heat-
inactivated FBS (Invitrogen) and 100 U/mL penicillin-
streptomycin (Sigma-Aldrich) in 5% CO2 at 37°C. SpSCC, 
HeLa, 293T, A549, NMuMG, HOC313, and HaCaT 
cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (Nissui Pharmaceutical Co. Ltd.) supplemented 
with 10% heat-inactivated FBS and 100 U/mL penicillin-
streptomycin in 5% CO2 at 37°C. For EMT induction, 
NMuMG and A549 cells were serum starved for 24 h 
and treated with 10 ng/mL human recombinant TGF-β1 
(Pepro Tech) for the indicated time. For the proliferation 
assay, 5000 cells were plated onto a 24-well plate and 
incubated for 0, 2, 4, and 6 days (n = 3). The cells were 
then trypsinized and counted using a cell counter (Coulter 
Z1, Beckman-Coulter). The average numbers of cells were 
compared and statistical assessment was carried out by the 
Mann-Whitney U-test. A P-value of < 0.05 was considered 
statistically significant.
miRNA microarray analysis
To compare miRNA expression profiles between 
MSCC-1 and MSCC-inv1, total RNAs extracted from 
each cell line using a mirVANATM miRNA Isolation Kit 
(Ambion) were analyzed with a 3D-Gene Human miRNA 
oligo chip (TORAY). The RT reaction was performed 
using MegaplexTM RT primers and human pool A, B 
(Applied Biosystems). The obtained cDNA was amplified 
with TaqMan® Human MicroRNA Array A, B using 
Real time PCR ABI7900HT (Applied Biosystems). The 
amplification reaction was monitored using SDS software 
v2.3 and the data were analyzed with RQ Manger 1.2.
Microarray analysis of immunoprecipitation 
products using anti-Ago2 antibody
Control- or miR-203-transfected cells were collected 
using a microRNA Isolation Kit, Human Ago2 (Wako), 
and miRNAs were isolated and immunoprecipitated with 
anti-Ago2 antibody. The purified miRNAs and target 
mRNAs, which form a complex with Ago2, were then 
obtained. The isolated mRNAs were analyzed using a 
3D-Gene Human Oligo chip 25k (TORAY).
RT-PCR
Total RNA was isolated from tumor cells using an 
RNeasy Mini Kit (Qiagen). These isolates were quantified 
and their purity was evaluated using a spectrophotometer. 
The cDNA was synthesized from 1 μg of total RNA 
according to ReverTra Dash (Toyobo Biochemicals). The 
primer sequences are shown in Supplemental Table 2. 
Total cDNA was amplified using Go Taq® Green Master 
Mix (Promega) in a My Cycler Thermal Cycler (Bio-
Rad) for 25-30 cycles of denaturation at 94°C for 30 s, 
annealing at 60°C for 30 s, and extension at 72°C for 30 s 
(for all primers). The amplicons were resolved on 1.2% 
agarose/TAE gels (Nacalai tesque Inc.) at 100 mV and 
visualized by ethidium bromide staining.
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Real-time PCR
To evaluate miRNAs, total RNA was isolated from 
cells using the miRNeasy Mini Kit (Qiagen). These 
isolates were quantified and their purity was evaluated 
using a spectrophotometer. The cDNA was synthesized 
from 10 ng of total RNA using a TaqMan® MicroRNA 
Assay and a TaqMan® MicroRNA Reverse transcription 
Kit (Applied Biosystems). Synthesized cDNA was 
amplified with a TaqMan® MicroRNA Assay and a 
TaqMan® Universal Master Mix II, no UNG (Applied 
Biosystems) using a Step One Plus Real-Time PCR 
system (Applied Biosystems) for 45 cycles of denaturation 
at 95°C for 15 s, and annealing and extension at 60°C for 
60 s. Data were normalized with U6 and each analysis 
was performed three times. The average of three trials 
was used for statistical analysis. ANOVA test was used 
for comparison of variables in more than two groups and 
a t-test was used for two groups. A P-value < 0.05 was 
considered statistically significant.
To evaluate mRNAs, the cDNA was synthesized 
from 1 μg of total RNA and amplified with KOD SYBR® 
qPCR Mix (Toyobo Biochemicals) and using a Step One 
Plus Real-Time PCR system (Applied Biosystems) for 
40 cycles of denaturation at 98°C for 10 s, annealing at 
60°C for 10 s, and extension at 68°C for 30 s. The primer 
sequences are shown in Supplemental Table 2. Data 
were normalized with GAPDH and each analysis was 
performed three times. The average of three trials was 
used for statistical analysis. The ANOVA test was used 
for comparison of variables in more than two groups and 
the t-test was used for two groups. A P-value < 0.05 was 
considered statistically significant.
Western blotting analysis
Sample protein concentrations were measured by 
the Bradford protein assay (Bio-Rad), and 20 μg total 
protein/lane was subjected to electrophoresis on 10% 
polyacrylamide gels followed by electroblotting onto 
nitrocellulose filters. The membranes were blocked 
with 3% milk in TBS-T and incubated overnight at 4°C 
with the following antibodies: anti-NUAK1 polyclonal 
antibody (Cell Signaling Technology, #4458), anti-
E-cadherin monoclonal antibody (BD Transduction 
Laboratories, 610181), anti-N-cadherin monoclonal 
antibody (BD Transduction Laboratories, 610920), anti-
SNAI1 polyclonal antibody (Cell Signaling Technology, 
#3879), anti-SNAI2 polyclonal antibody (Cell Signaling 
Technology, #9585), anti-ZEB1 antibody (Santa Cruz 
Biotechnology, sc-25388), anti-vimentin monoclonal 
antibody (Dako, #M0725), and anti-β-actin polyclonal 
antibody (Sigma-Aldrich, A5441). The membranes were 
then washed with TBS-T and incubated with specific 
secondary antibodies, and the proteins were visualized 
using the ECL western blotting detection system (GE 
Healthcare).
In vitro invasion assay
The membrane of a 24-well cell culture insert with 
8 μm pores (BD Transduction Laboratories) was coated 
with 20 μg of Matrigel (BD Transduction Laboratories). 
1.5 × 105 cells were resuspended in 100 μL of medium and 
placed in the upper compartment of the cell culture insert. 
The lower component was filled with 500 μL of medium. 
After incubation at 37°C for the indicated time, the cells 
that penetrated the membrane into the lower side were 
fixed with formalin, and were stained with hematoxylin. 
Cells were counted in three individual fields on each 
insert. The average was used for the t-test. A P-value < 
0.05 was considered statistically significant.
Transient miRNA/siRNA transfection
A hsa-miRNAs duplex was obtained from Cosmo 
Bio (miCENTURY OX miNatural, hsa-miR-203). Anti-
miR-203 (Ambion® Anti-miR™ miRNA Inhibitor, 
product number AM10152) was used as a miR-203 
inhibitor. Anti-miR-203 is a single-stranded nucleic 
acid and is designed to specifically bind to and inhibit 
endogenous miRNA molecules. Because anti-miR-203 
downregulates miRNA activity, the mRNA level of miR-
203 does not always reflect the effect of the inhibitor. 
In this study, we confirmed upregulation of SNAI2 and 
VEGFA mRNA as a known target of miR-203 (Figure 
4D). Cells were transfected with 5 nM hsa-miRNAs 
and with 5-100 nM anti-miR-203 using Lipofectamine 
RNAiMax (Invitrogen). siRNAs targeting NUAK1 and 
negative control siRNA were purchased from Santa Cruz 
Biotechnology. The siNUAK1 used in this study contained 
three to five target-specific 19-25 nt siRNAs designed 
to knockdown gene expression. Cells were transfected 
with 35 nM siNUAK1 using X-tremeGENE HP (Roche 
Applied Science). After incubation for 48 h, the cells were 
used for each analysis.
Lentivirus infection
Lentiviruses were generated by cotransfecting 
0.9 μg of lentiviral vector (premiR-203 or scramble 
negative control vectors, System Biosciences) and 2.7 
μg of packaging plasmid mix (1:1:1 for 0.9 μg pPACK-
H1-GAG, pPACK-H1-Rev, and pVSV-G) in 293T cells 
using Lipofectamine LTX Plus reagent (Invitrogen). 
Supernatants were collected 48 h after transfection, filtered 
through a 0.45-μm membrane, and directly used to infect 
cells. Two weeks after infection of lentiviruses containing 
pre-miR-203 or scramble negative control vectors with 
GFP, GFP-expressing cells were sorted by flow cytometry 
to obtain stable pre-miR-203-expressing cells.
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Luciferase reporter assay
The sense and antisense oligonucleotides for the 
putative miR-203 binding site at the 3ʹ-UTR of SNAI2 
were annealed and cloned into a pmirGLO vector 
(Promega). The oligonucleotides had the following 
sequences:
SNAI2-1: 5’-CATTGCTGCCAAATCATTTCAA-3’
SNAI2-2: 5’-TTACTATTTTAAAACATTTTAA-3’
SNAI2-3: 5’-TAATGTACTTAAACTATTTCAA-3’
The full-length 3ʹ-UTR of human NUAK1 was 
amplified by PCR (Supplemental Table 2) from genomic 
DNA and cloned at the EcoRI site into the pmirGLO 
vector (Promega). These constructs were confirmed by 
sequencing. For luciferase activity analysis, these vectors 
were cotransfected with the miRNA duplex in 293T using 
DharmaFECT Duo Transfection Reagent (Thermo Fisher 
Scientific) for 72 h, and luciferase assays were performed 
with the Dual-Luciferase reporter system (Promega). 
Luminescent signals were quantified by luminometer 
(Glomax; Promega), and each value from the firefly 
luciferase construct was normalized by Renilla luciferase 
activity. The average of three individual trials was used 
for the t-test. A P-value < 0.05 was considered statistically 
significant.
Tissue samples
For immunohistochemical examination, 54 tissue 
samples of HNSCC were retrieved from the Surgical 
Pathology Registry of Hiroshima University Hospital from 
1998 to 2004, after approval by the Ethical Committee 
of our institutions. Cases of T2 were used for analysis 
and 10% buffered formalin-fixed and paraffin-embedded 
tissues were used. The histological grade and stage of 
the tumors were classified according to the criteria of 
the Japan Society for Head and Neck Cancer. For the 
invasion pattern, we used the Yamamoto-Kohama (YK) 
classification, which is based on histological architecture 
and mode of invasion. The YK classification is categorized 
into 5 grades: grade 1, well defined borderline; 2, cords, 
less marked borderline; 3, groups of cells, no distinct 
borderline; 4C, diffuse invasion with cord-like type; and 
4D, with diffuse type invasion [49].
For real-time PCR analysis, 33 patients (16 men, 
17 women; 44-91 years of age, mean: 67.1 years) with 
primary HNSCCs, who received treatment at Nara 
Medical University Hospital, Kashihara, Japan between 
2003 and 2006, were randomly selected. All cases were 
performed without pre-operative therapy before surgery 
and sample preparation took place after approval by 
the Medical Ethical Committee of the Nara Medical 
University.
Immunohistochemistry
Tissue sections were deparaffinized in xylene and 
rehydrated in descending grades of ethanol. Endogenous 
peroxidase activity was blocked with methanol containing 
0.3% H2O2 for 30 min. Antigen retrieval was carried 
out by Pascal Pressure Chamber (Dako) using Dako 
Target Retrieval Solution, pH 9.0 (Dako) for 30 s at 
125°C. After treatment with casein for prevention of 
non-specific background for 10 min, the sections were 
treated with polyclonal anti-NUAK1 antibody (Cell 
Signaling Technology, 1:50) using a MI-77 microwave 
oven (Azumaya Company) for 30 min (4 s on and 4 s off) 
followed by incubation at 4°C overnight. After incubation 
with secondary antibody, the reaction was detected by 
3,3ʹ-diaminobenzidine (Dako). The sections were then 
counterstained with hematoxylin, and dehydrated in 
ascending grades of ethanol, and finally the slides were 
mounted. Correlation between the immunohistochemical 
staining of NUAK1 and histological differentiation, 
pattern of invasion, and lymph node metastasis was 
analyzed and the significance was validated by the Fisher’s 
exact test.
Analysis of the methylation status
DNA was extracted and purified from cells using 
a DNeasy® Tissue Kit (Qiagen) and 500 ng DNA was 
bisulfited with a MethylCodeTM Bisulfite Conversion 
Kit (Invitrogen) and amplified by HotStarTaq® DNA 
polymerase (Qiagen) and U and M primers; the U primer 
detected unmethylated sequences and the M primer 
detected methylated sequences (Supplemental Table 2). 
Amplification was performed for 40 cycles of denaturation 
at 94°C for 30 s, annealing at 54°C for 30 s, and extension 
at 72°C for 60 s. The amplicons were resolved on 1.5% 
agarose/TAE gels (Nacalai Tesque) at 100 mV and 
visualized by ethidium bromide staining. To demethylate 
the target cells, cells were incubated with the medium 
containing 5 μM 5-asa-2’-deoxyxytidine (5-aza-dC) 
(Sigma-Aldrich) for 48 h or the indicated time.
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